Dr.Β HagopΒ Kantarjian
MD, ABIM, ABMO, ABH
Professor, Department of Leukemia, Division of Cancer Medicine
corporate_fareMD Anderson Cancer Center, Houston, USA
Hagop Kantarjian
MD, ABIM, ABMO, ABH
Dr. Hagop M. Kantarjian is an internationally recognised leukaemia specialist and Professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. He holds the Samsung Distinguished University Chair in Cancer Medicine and serves as a non-resident fellow in health policy at Rice University's Baker Institute.
With more than four decades at MD Anderson, Dr. Kantarjian served as Chair of the Department of Leukemia from 1995 to 2025 before transitioning to his current professorial role. His clinical and translational research has contributed to the approval of more than 20 leukaemia drugs and his work on tyrosine kinase inhibitors transformed outcomes for patients with chronic myeloid leukaemia. He has authored more than 2,400 peer-reviewed publications and his research spans CML, ALL, AML, and myelodysplastic syndromes. He is one of the most cited oncologists in the world and has received major lifetime achievement awards from ASCO, AACR, and leading international oncology societies.
MD Anderson Cancer Center has a dedicated International Center supporting patients from outside the United States. CancerFax can coordinate medical-report submission and consultation support as part of the process.
Why Consider Dr. Hagop Kantarjian?
Dr. Kantarjian is among the most influential leukaemia clinician-scientists in the world. His four-decade career at MD Anderson, prolific research output, and central role in drug development make him a key reference point for patients with complex or refractory leukaemia.
Areas of Specialisation
Focused exclusively on leukaemia and related blood cancers across four decades
Dr. Kantarjian's entire career has been devoted to the treatment, research, and clinical investigation of adult leukaemia and haematologic malignancies. His practice encompasses targeted therapy, chemotherapy-based regimens, immunotherapy, clinical trial evaluation, and precision oncology for patients with chronic and acute leukaemia.
Chronic Myeloid Leukaemia (CML)
Pioneering contributions to TKI-based therapy have made CML a manageable condition for many patients.
- arrow_rightImatinib, dasatinib, nilotinib, and bosutinib-based regimens
- arrow_rightTreatment selection based on molecular and cytogenetic response
- arrow_rightManagement of TKI resistance and intolerance
- arrow_rightEvaluation of eligibility for TKI discontinuation
- arrow_rightMonitoring protocols for deep molecular remission
Acute Lymphoblastic Leukaemia (ALL)
Developer of the Hyper-CVAD regimen and contributor to subsequent immunotherapy-based advances in ALL treatment.
- arrow_rightHyper-CVAD and related chemotherapy protocols for adult ALL
- arrow_rightCombination approaches integrating targeted and immunotherapy agents
- arrow_rightBlinatumomab (bispecific T-cell engager) for relapsed/refractory ALL
- arrow_rightInotuzumab ozogamicin-based treatment approaches
Acute Myeloid Leukaemia (AML)
Extensive clinical research and drug development contributions across the AML treatment landscape.
- arrow_rightInduction chemotherapy and consolidation strategies
- arrow_rightTargeted agents for FLT3, IDH1/IDH2, and other actionable mutations
- arrow_rightVenetoclax-based combinations for eligible patients
- arrow_rightClinical trial evaluation for relapsed/refractory disease
- arrow_rightSalvage regimens and bridge-to-transplant planning
Myelodysplastic Syndromes (MDS)
Contributor to the development of hypomethylating agent therapy for MDS.
- arrow_rightDecitabine and azacitidine-based regimens
- arrow_rightRisk-stratified treatment planning based on IPSS-R scoring
- arrow_rightManagement of treatment failure and transition to higher-risk MDS
Procedures & Treatment Approaches
Medical oncology and developmental therapeutics for leukaemia and blood cancers
Dr. Kantarjian's practice is centred on systemic and targeted treatment for adult leukaemia. His approach integrates evidence-based chemotherapy, targeted molecular therapy, immunotherapy, and clinical trial access within MD Anderson's multidisciplinary blood cancer programme.
Leukaemia Diagnosis & Treatment Planning
DiagnosisComprehensive evaluation integrating cytogenetics, molecular profiling, and bone marrow analysis to guide treatment selection.
Targeted Therapy for Leukaemia
Targeted TherapyMolecularly guided targeted treatment for CML, ALL, and AML based on mutation and fusion gene status.
Chemotherapy-Based Leukaemia Treatment
Medical OncologyStandard and intensive chemotherapy regimens for acute and chronic leukaemia including the Hyper-CVAD protocol.
Immunotherapy for Blood Cancers
Medical OncologyAntibody-based and cellular immunotherapy approaches for eligible leukaemia patients.
Clinical Trial-Based Leukaemia Care
Complex DiseaseAccess to investigational agents and novel treatment combinations through MD Anderson's active clinical trial programme.
Second Opinion for Leukaemia
Second OpinionIndependent expert review of leukaemia diagnosis, pathology, molecular results, and existing treatment plans.
Research & Publications
More than 2,400 peer-reviewed publications and contributions to 20+ approved leukaemia therapies
Dr. Kantarjian is one of the most prolific and widely cited leukaemia researchers in the world. His translational research has directly shaped modern treatment standards for CML, ALL, AML, and MDS. MD Anderson's institutional research profile lists more than 2,700 research outputs in Scopus-indexed records.
A comprehensive publication list is available on PubMed and through MD Anderson's faculty research profile. Dr. Kantarjian's full Scopus-indexed output exceeds 2,700 research records.
Education & Training
Dr. Kantarjian completed his medical training at the American University of Beirut before undertaking advanced fellowship training in developmental therapeutics and haematology-oncology at MD Anderson Cancer Center, where he has spent his entire subsequent career.
Clinical Experience
Dr. Kantarjian has spent his entire career at MD Anderson Cancer Center, where he progressed from fellow to department faculty and served as Chair of the Department of Leukemia from 1995 to 2025 β one of the longest tenures in the institution's history.
Languages & International
Dr. Kantarjian consults in the following language. CancerFax can coordinate professional medical interpreter support for international patients where required.
CancerFax coordinates professional medical interpreter support for international patients as part of the consultation coordination process.
CancerFax can coordinate certified medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Hagop Kantarjian
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Hagop Kantarjian's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Hagop Kantarjian's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Hagop Kantarjian before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Hagop Kantarjian's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Hagop Kantarjian's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Hagop Kantarjian's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Hagop Kantarjian
Dr. Kantarjian specialises exclusively in leukaemia and blood cancers, including chronic myeloid leukaemia (CML), acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), and myelodysplastic syndromes (MDS). He also treats patients with relapsed or refractory haematologic malignancies.
Dr. Kantarjian is based at The University of Texas MD Anderson Cancer Center in Houston, Texas β one of the world's most respected cancer hospitals and a National Cancer Institute-designated Comprehensive Cancer Center.
MD Anderson Cancer Center has a dedicated International Center that supports patients travelling from outside the United States. Services may include appointment coordination, medical record submission, interpreter support, and travel preparation. CancerFax can assist with medical report submission and coordination as part of the consultation process, subject to availability and case acceptance by the hospital.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documentation, prepare a structured case summary, and coordinate the next steps with MD Anderson, subject to availability. For second opinion requests, pathology reports, imaging studies, bone marrow results, and prior treatment records should be included.
According to MD Anderson, remote second opinions are not offered at this time. Second opinion consultations are treated as standard new patient appointments and typically require an in-person visit, which may include blood tests, imaging review, and evaluation of bone marrow or tissue samples. Please confirm current availability and process directly with MD Anderson or through the CancerFax coordination pathway.
Dr. Kantarjian's treatment approaches include tyrosine kinase inhibitor therapy for CML, Hyper-CVAD-based chemotherapy for ALL, targeted agents for AML including FLT3 and IDH inhibitors, hypomethylating agents for MDS, antibody-based immunotherapy such as blinatumomab and inotuzumab, and clinical trial access for patients with relapsed or refractory disease.
Dr. Kantarjian has authored more than 2,400 peer-reviewed publications according to MD Anderson's faculty profile, with institutional Scopus-indexed records listing over 2,700 research outputs. He has been recognised as a Clarivate Highly Cited Researcher from 2014 to 2024.
Connect with Hagop Kantarjian Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.